MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • China Botanic Pharmaceutical Inc. (CBP) Receives Patent for Siberian Ginseng Extraction Process 0 comments
    Jun 30, 2011 6:03 PM | about stocks: CBP
    China Botanic Pharmaceutical Inc. is a company on the rise. Located in Harbin, China, this young company has quickly earned a reputation for their research, development, manufacturing, and distribution of botanical products and bio-pharmaceutical products. Today, China Botanic took a major step towards prominence with announcement they have been granted a patent from the State Intellectual Property Office of the People’s Republic of China for its Siberian Ginseng.
    The patent is No. ZL200710301682X and will not only protect the Siberian Ginseng (Acanthopanax) but will also protect the resulting Siberian Ginseng extracts and their application will provide market exclusivity for a period of 20 years.
    The patent covers a wide variety of possible Siberian Ginseng extraction methods and applications, creating a high barrier to entry for competitors seeking to develop similar Siberian Ginseng products, and, as a result, it confers significant independent intellectual property rights. These medicines are state-of-the-art in that they are powerful new tools in combating depression and senile dementia and have been recognized as “class one new drugs” and “innovative drugs” by the State Food and Drug Administration of China.
    Leading the team at China Botanic is Mr. Shaomin Li whom serves as the Chairman and CEO of the evolving company. Li stated, “It is highly gratifying to receive patent protection for our advancements in the treatment of depression using all-natural Siberian Ginseng extracts. With our exclusive access to a large proportion of the Siberian Ginseng resources, and now this important protection for the extracts we obtain from the plant, our methods of preparation and their applications, we feel this is a major step forward. The issuance of this patent will enhance the commercial potential of our Siberian Ginseng applications in China, one of the largest markets for depression therapies, and further strengthen our leading market position.”
    Currently, China Botanic is trading in the $0.80 range. To learn more about their new patent and the company as a whole, visit the corporate website at: renhuang.com
    Please see disclaimer on the MissionIR website www.missionir.com/disclaimer.html 
    Stocks: CBP
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.